Nikolaos Kentepozidis

Author

Hellenic Oncology Research Group ORCID

Also Known As

Kentepozidis, Nikolaos, Manuel Cobo, N Kentepozidis, N. Kentepozidis, NIKOLAOS KENTEPOZIDIS, Nikolaos Kentepozidis

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

Hellenic Oncology Research Group University Hospital of Heraklion National and Kapodistrian University of Athens Hellenic Airforce General Hospital 401 General Military Hospital of Athens

About

Nikolaos Kentepozidis is an author at Hellenic Oncology Research Group specializing in medicine, cancer therapeutics, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	23	538
2	Health Sciences	4	4	81
3	Geriatrics	2	2	44
4	Microbiology	2	2	55
5	Immunology	1	1	64

Nikolaos Kentepozidis

Publications

Citations

H-Index

Page 1

	Year	Citations
Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients Αthanasios Kotsakis, Filippos Koinis, Afroditi Katsarou, Scientific Reports	2016	95
A phase II trial evaluating the clinical and immunologic response of HLA-A2+ non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide Αthanasios Kotsakis, E. Papadimitraki, Eleni‐Kyriaki Vetsika, Lung Cancer VaccinationHtert Cryptic PeptideCancer ImmunosurveillancePhase Ii TrialMedicine	2014	64
Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC) John Souglakos, N. Ziras, Stylianos Kakolyris, British Journal of Cancer	2012	64
A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group Emmanouil Kontopodis, Dora Hatzidaki, Ioannis Varthalitis, Journal of Chemotherapy	2013	48
Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project John Souglakos, Ioannis Boukovinas, Stylianos Kakolyris, Annals of Oncology High-risk Stage IiOncologyGastrointestinal OncologyCancer ManagementAdjuvant Chemotherapy	2019	46
Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer Dimitriοs Mavroudis, Pavlos Papakotoulas, Alexandros Ardavanis, Annals of Oncology Advanced Breast CancerBreast OncologyOncologyMedicinePhase Iii Trial	2009	44
Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group Filippos Koinis, Sofia Agelaki, V. Karavassilis, British Journal of Cancer	2017	43
Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group Elena Fountzilas, Sofia Lampaki, Georgia-Angeliki Koliou, Cancer Immunology Immunotherapy	2021	39
Continuous Administration of Daily Low-Dose Temozolomide in Pretreated Patients with Advanced Non-Small Cell Lung Cancer: A Phase II Study Charalambos Kouroussis, Lambros Vamvakas, Nikolaos Vardakis, Oncology	2009	36
A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer Athanasios Pallis, Athina Agelidou, Ioannis Varthalitis, BMC Cancer	2010	35

Page 1